Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Hepcidin Market by Type (DS-79182026, M-009, PRS-080, PTG-300, Others), By Application (Acute Inflammation, Anemia, Iron Deficiency Anemia, Sickle Cell Disease, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Hepcidin Market by Type (DS-79182026, M-009, PRS-080, PTG-300, Others), By Application (Acute Inflammation, Anemia, Iron Deficiency Anemia, Sickle Cell Disease, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 194388 3300 Pharma & Healthcare 377 250 Pages 4.6 (48)
                                          

The global hepcidin market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing prevalence of anemia and iron deficiency anemia, which are major causes for hepcidin production. The increasing prevalence of these diseases is also due to the growing population and aging population in developing countries such as China and India. The global hepcidin market by type is segmented into D79182026, 009, PR080, PT300. D79182026 accounted for the largest share in 2018 owing to its high therapeutic efficacy against inflammation-related diseases such as acute inflammation and sickle cell disease. 009 accounted for the second-largest share owing to its high therapeutic efficacy against anemia-related diseases such as iron deficiency anemia and sickle cell disease. PR080 accounted for a small share owing to its low therapeutic efficacy against inflammation-related diseases such as acute inflammation and sickle cell disease but has high therapeutic efficacy against anemia-related diseases such as iron deficiency anemia and sickle cell disease. PT300 accounted for a small share owing to its low therapeutic efficacy against both types of diseases but has high safety profile with no side effects observed so far in clinical trials conducted on humans or animals.

Some Of The Growth Factors Of This Market:

  1. The Hepcidin market is expected to grow due to the increasing prevalence of chronic liver diseases and the rising incidence of cirrhosis.
  2. The Hepcidin market is expected to grow due to the increasing number of patients with chronic kidney disease and end-stage renal disease, which are associated with an increased risk for hepatic encephalopathy.
  3. The Hepcidin market is expected to grow due to the increasing number of patients with diabetes mellitus type 2, which are associated with an increased risk for hepatic encephalopathy.
  4. The Hepcidin market is expected to grow due to the increase in awareness about liver health among people who have a family history or genetic predisposition for liver diseases such as hemochromatosis or Wilson's Disease, which are associated with an increased risk for hepatic encephalopathy.

Industry Growth Insights published a new data on “Hepcidin Market”. The research report is titled “Hepcidin Market research by Types (DS-79182026, M-009, PRS-080, PTG-300, Others), By Applications (Acute Inflammation, Anemia, Iron Deficiency Anemia, Sickle Cell Disease, Others), By Players/Companies Daiichi Sankyo Co Ltd, Pieris Pharmaceuticals Inc, Protagonist Therapeutics Inc, Noxxon Pharma AG”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Hepcidin Market Research Report

By Type

DS-79182026, M-009, PRS-080, PTG-300, Others

By Application

Acute Inflammation, Anemia, Iron Deficiency Anemia, Sickle Cell Disease, Others

By Companies

Daiichi Sankyo Co Ltd, Pieris Pharmaceuticals Inc, Protagonist Therapeutics Inc, Noxxon Pharma AG

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

250

Number of Tables & Figures

175

Customization Available

Yes, the report can be customized as per your need.


Global Hepcidin Industry Outlook


Global Hepcidin Market Report Segments:

The global Hepcidin market is segmented on the basis of:

Types

DS-79182026, M-009, PRS-080, PTG-300, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Acute Inflammation, Anemia, Iron Deficiency Anemia, Sickle Cell Disease, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Daiichi Sankyo Co Ltd
  2. Pieris Pharmaceuticals Inc
  3. Protagonist Therapeutics Inc
  4. Noxxon Pharma AG

Global Hepcidin Market Overview


Highlights of The Hepcidin Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. DS-79182026
    2. M-009
    3. PRS-080
    4. PTG-300
    5. Others
  1. By Application:

    1. Acute Inflammation
    2. Anemia
    3. Iron Deficiency Anemia
    4. Sickle Cell Disease
    5. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Hepcidin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Hepcidin Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Hepcidin is a protein that helps the body to rid itself of toxins.

Some of the key players operating in the hepcidin market are Daiichi Sankyo Co Ltd, Pieris Pharmaceuticals Inc, Protagonist Therapeutics Inc, Noxxon Pharma AG.

The hepcidin market is expected to register a CAGR of 5.5%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Hepcidin Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Hepcidin Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Hepcidin Market - Supply Chain
   4.5. Global Hepcidin Market Forecast
      4.5.1. Hepcidin Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Hepcidin Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Hepcidin Market Absolute $ Opportunity

5. Global Hepcidin Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Hepcidin Market Size and Volume Forecast by Type
      5.3.1. DS-79182026
      5.3.2. M-009
      5.3.3. PRS-080
      5.3.4. PTG-300
      5.3.5. Others
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Hepcidin Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Hepcidin Market Size and Volume Forecast by Application
      6.3.1. Acute Inflammation
      6.3.2. Anemia
      6.3.3. Iron Deficiency Anemia
      6.3.4. Sickle Cell Disease
      6.3.5. Others
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Hepcidin Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Hepcidin Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Hepcidin Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Hepcidin Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Hepcidin Demand Share Forecast, 2019-2026

9. North America Hepcidin Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Hepcidin Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Hepcidin Market Size and Volume Forecast by Application
      9.4.1. Acute Inflammation
      9.4.2. Anemia
      9.4.3. Iron Deficiency Anemia
      9.4.4. Sickle Cell Disease
      9.4.5. Others
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Hepcidin Market Size and Volume Forecast by Type
      9.7.1. DS-79182026
      9.7.2. M-009
      9.7.3. PRS-080
      9.7.4. PTG-300
      9.7.5. Others
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Hepcidin Demand Share Forecast, 2019-2026

10. Latin America Hepcidin Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Hepcidin Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Hepcidin Market Size and Volume Forecast by Application
      10.4.1. Acute Inflammation
      10.4.2. Anemia
      10.4.3. Iron Deficiency Anemia
      10.4.4. Sickle Cell Disease
      10.4.5. Others
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Hepcidin Market Size and Volume Forecast by Type
      10.7.1. DS-79182026
      10.7.2. M-009
      10.7.3. PRS-080
      10.7.4. PTG-300
      10.7.5. Others
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Hepcidin Demand Share Forecast, 2019-2026

11. Europe Hepcidin Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Hepcidin Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Hepcidin Market Size and Volume Forecast by Application
      11.4.1. Acute Inflammation
      11.4.2. Anemia
      11.4.3. Iron Deficiency Anemia
      11.4.4. Sickle Cell Disease
      11.4.5. Others
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Hepcidin Market Size and Volume Forecast by Type
      11.7.1. DS-79182026
      11.7.2. M-009
      11.7.3. PRS-080
      11.7.4. PTG-300
      11.7.5. Others
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   1.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Hepcidin Demand Share, 2019-2026

12. Asia Pacific Hepcidin Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Hepcidin Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Hepcidin Market Size and Volume Forecast by Application
      12.4.1. Acute Inflammation
      12.4.2. Anemia
      12.4.3. Iron Deficiency Anemia
      12.4.4. Sickle Cell Disease
      12.4.5. Others
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Hepcidin Market Size and Volume Forecast by Type
      12.7.1. DS-79182026
      12.7.2. M-009
      12.7.3. PRS-080
      12.7.4. PTG-300
      12.7.5. Others
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Hepcidin Demand Share, 2019-2026

13. Middle East & Africa Hepcidin Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Hepcidin Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Hepcidin Market Size and Volume Forecast by Application
      13.4.1. Acute Inflammation
      13.4.2. Anemia
      13.4.3. Iron Deficiency Anemia
      13.4.4. Sickle Cell Disease
      13.4.5. Others
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Hepcidin Market Size and Volume Forecast by Type
      13.7.1. DS-79182026
      13.7.2. M-009
      13.7.3. PRS-080
      13.7.4. PTG-300
      13.7.5. Others
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Hepcidin Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Hepcidin Market: Market Share Analysis
   14.2. Hepcidin Distributors and Customers
   14.3. Hepcidin Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Daiichi Sankyo Co Ltd
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Pieris Pharmaceuticals Inc
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Protagonist Therapeutics Inc
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Noxxon Pharma AG
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. COMPANY5
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. COMPANY6
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. COMPANY7
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. COMPANY8
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. COMPANY9
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. COMPANY 10
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. COMPANY 11
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us